WALTHAM, Mass.--(BUSINESS WIRE)--Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has entered into a Non-Clinical Evaluation Agreement to access the National Institute of Allergy and Infectious Diseases’ (NIAID’s) preclinical services program to further evaluate AVL-192, Avila’s targeted, irreversible covalent inhibitor of the HCV protease (NS3). Under the agreement, NIAID-funded contractors are conducting preclinical studies of AVL-192 to help enable its future clinical development, and Avila retains exclusive rights to this compound.
